146 related articles for article (PubMed ID: 20099118)
21. Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04.
Boland G; Beran J; Lievens M; Sasadeusz J; Dentico P; Nothdurft H; Zuckerman JN; Genton B; Steffen R; Loutan L; Van Hattum J; Stoffel M
Vaccine; 2004 Dec; 23(3):316-20. PubMed ID: 15530674
[TBL] [Abstract][Full Text] [Related]
22. Monophosphoryl lipid A analogues with varying 3-O-substitution: synthesis and potent adjuvant activity.
Jiang ZH; Budzynski WA; Qiu D; Yalamati D; Koganty RR
Carbohydr Res; 2007 May; 342(6):784-96. PubMed ID: 17300769
[TBL] [Abstract][Full Text] [Related]
23. Supplementation of whole-cell pertussis vaccines with lipopolysaccharide analogs: modification of vaccine-induced immune responses.
Geurtsen J; Fransen F; Vandebriel RJ; Gremmer ER; de la Fonteyne-Blankestijn LJ; Kuipers B; Tommassen J; van der Ley P
Vaccine; 2008 Feb; 26(7):899-906. PubMed ID: 18207288
[TBL] [Abstract][Full Text] [Related]
24. Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency.
Kazzaz J; Singh M; Ugozzoli M; Chesko J; Soenawan E; O'Hagan DT
J Control Release; 2006 Feb; 110(3):566-73. PubMed ID: 16360956
[TBL] [Abstract][Full Text] [Related]
25. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.
Evans JT; Cluff CW; Johnson DA; Lacy MJ; Persing DH; Baldridge JR
Expert Rev Vaccines; 2003 Apr; 2(2):219-29. PubMed ID: 12899573
[TBL] [Abstract][Full Text] [Related]
26. [Editorial of the "vaccination issue" of KMIL--what have demonstrated Prevenar and Fendrix vaccines].
Beran J
Klin Mikrobiol Infekc Lek; 2006 Jun; 12(3):87-90. PubMed ID: 17051468
[TBL] [Abstract][Full Text] [Related]
27. Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice.
Quintilio W; Kubrusly FS; Iourtov D; Miyaki C; Sakauchi MA; Lúcio F; Dias Sde C; Takata CS; Miyaji EN; Higashi HG; Leite LC; Raw I
Vaccine; 2009 Jun; 27(31):4219-24. PubMed ID: 19393709
[TBL] [Abstract][Full Text] [Related]
28. TLR4 agonists as immunomodulatory agents.
Alderson MR; McGowan P; Baldridge JR; Probst P
J Endotoxin Res; 2006; 12(5):313-9. PubMed ID: 17059695
[TBL] [Abstract][Full Text] [Related]
29. Vaccine adjuvants: the dream becomes real.
Tagliabue A; Rappuoli R
Hum Vaccin; 2008; 4(5):347-9. PubMed ID: 18682690
[TBL] [Abstract][Full Text] [Related]
30. Lactoferrin-monophosphoryl lipid A complex enhances immunity of mice to Plesiomonas shigelloides CNCTC 138/92.
Chodaczek G; Zimecki M; Lukasiewicz J; Lugowski C
Acta Biochim Pol; 2008; 55(1):91-6. PubMed ID: 18231655
[TBL] [Abstract][Full Text] [Related]
31. T cell and interferon-gamma involvement in the adjuvant action of a detoxified endotoxin.
Tomai MA; Johnson AG
J Biol Response Mod; 1989 Dec; 8(6):625-43. PubMed ID: 2513379
[TBL] [Abstract][Full Text] [Related]
32. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
[TBL] [Abstract][Full Text] [Related]
33. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.
Cluff CW
Adv Exp Med Biol; 2010; 667():111-23. PubMed ID: 20665204
[TBL] [Abstract][Full Text] [Related]
34. Monophosphoryl lipid A-induced immune enhancement of Brucella abortus salt-extractable protein and lipopolysaccharide vaccines in BALB/c mice.
Tabatabai LB; Pugh GW; Stevens MG; Phillips M; McDonald TJ
Am J Vet Res; 1992 Oct; 53(10):1900-7. PubMed ID: 1456539
[TBL] [Abstract][Full Text] [Related]
35. Effect of monophosphoryl lipid A on antibody response to diphtheria toxin and its subunits.
Caglar K; Aybay C; Ataoglu H
APMIS; 2005 Apr; 113(4):256-63. PubMed ID: 15865606
[TBL] [Abstract][Full Text] [Related]
36. Pollinex Quattro Ragweed: safety evaluation of a new allergy vaccine adjuvanted with monophosphoryl lipid A (MPL) for the treatment of ragweed pollen allergy.
Baldrick P; Richardson D; Woroniecki SR; Lees B
J Appl Toxicol; 2007; 27(4):399-409. PubMed ID: 17299813
[TBL] [Abstract][Full Text] [Related]
37. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives.
Garçon N; Chomez P; Van Mechelen M
Expert Rev Vaccines; 2007 Oct; 6(5):723-39. PubMed ID: 17931153
[TBL] [Abstract][Full Text] [Related]
38. Comparison of liposome-polycation-DNA(LPD) and monophosphoryl lipid A(MPL) adjuvant formulations in BALB/c mice models.
Zhang XP; Cui WH
Immunol Invest; 2012; 41(4):356-66. PubMed ID: 21864115
[TBL] [Abstract][Full Text] [Related]
39. The safety evaluation of adjuvants during vaccine development: the AS04 experience.
Garçon N; Segal L; Tavares F; Van Mechelen M
Vaccine; 2011 Jun; 29(27):4453-9. PubMed ID: 21527299
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the effects of five adjuvants on the antibody response to influenza virus antigen in guinea pigs.
Robuccio JA; Griffith JW; Chroscinski EA; Cross PJ; Light TE; Lang CM
Lab Anim Sci; 1995 Aug; 45(4):420-6. PubMed ID: 7474883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
